Patents by Inventor Edward S. Cole

Edward S. Cole has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Transgenically produced antithrombin III
    Patent number: 7928064
    Abstract: This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GalNAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.
    Type: Grant
    Filed: November 14, 2005
    Date of Patent: April 19, 2011
    Assignee: GTC Biotherapeutics, Inc.
    Inventors: Paul DiTullio, Harry M. Meade, Edward S. Cole
  • Transgenically produced antithrombin III
    Publication number: 20080176786
    Abstract: This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GalNAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.
    Type: Application
    Filed: November 14, 2005
    Publication date: July 24, 2008
    Inventors: Paul Ditullio, Harry M. Meade, Edward S. Cole
  • Treatments using transgenic goat produced antithrombin III
    Patent number: 7019193
    Abstract: This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GalNAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.
    Type: Grant
    Filed: July 2, 2002
    Date of Patent: March 28, 2006
    Assignee: GTC Biotherapeutics, Inc.
    Inventors: Paul Ditullio, Harry M. Meade, Edward S. Cole
  • Transgenically produced antithrombin III
    Publication number: 20030096974
    Abstract: This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GalNAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.
    Type: Application
    Filed: July 2, 2002
    Publication date: May 22, 2003
    Applicant: Genzyme Transgenics Corporation, a Massachusetts corporation
    Inventors: Paul Ditullio, Harry M. Meade, Edward S. Cole
  • Transgenically produced Antithrombin III
    Patent number: 6441145
    Abstract: This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GaINAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.
    Type: Grant
    Filed: August 28, 1998
    Date of Patent: August 27, 2002
    Assignee: Genzyme Transgenics, Inc.
    Inventors: Paul DiTullio, Harry Meade, Edward S. Cole
  • Transgenically produced antithrombin III
    Patent number: 5843705
    Abstract: This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GaINAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.
    Type: Grant
    Filed: February 21, 1995
    Date of Patent: December 1, 1998
    Assignee: Genzyme Transgenic Corporation
    Inventors: Paul DiTullio, Harry Meade, Edward S. Cole
  • Isolation of components of interest from milk
    Patent number: 5756687
    Abstract: Methods of isolating components of interest from a milk sample are described. The methods include a step wherein the solubility of at least a portion of the total milk protein is stabilized in such a manner as to allow isolation of the component of interest without significant loss in yield. Kits for stabilizing the solubility of at least a portion of the total milk protein of the milk sample containing the component of interest also are described.
    Type: Grant
    Filed: January 23, 1995
    Date of Patent: May 26, 1998
    Assignee: Genzyme Transgenics Corporation
    Inventors: Julie S. Denman, Edward S. Cole
  • Human uterine tissue plasminogen activator produced by recombinant DNA
    Patent number: 5344773
    Abstract: A replicable expression vector capable, in a transformed host mammallian cell, of expressing a DNA sequence encoding active human TPA which, when expressed in the host cell, yields active TPA which lacks one or more of the TPA-bound N-linked carbohydrate moieties of naturally occurring human TPA.
    Type: Grant
    Filed: October 1, 1985
    Date of Patent: September 6, 1994
    Assignee: Genzyme Corporation
    Inventors: Cha-Mer Wei, Nancy Hsiung, Vermuri B. Reddy, Jeffrey F. Lemontt, William Dackowski, Richard Douglas, Edward S. Cole, Richard D. Purcell, Jr., David Tai-Yui Lau